Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)

11. september 2026 oppdatert av: Gilead Sciences

En fase 3, dobbeltblind, multisenter, randomisert studie for å evaluere effektiviteten og sikkerheten til subkutan to ganger årlig langtidsvirkende Lenacapavir for HIV pre-eksponeringsprofylakse hos ciskjønnede menn, transkjønnede kvinner, transkjønnede menn og ikke-binære kjønnspersoner ≥ 16 år med Alder som har sex med mannlige partnere og er i faresonen for HIV-infeksjon

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.

The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

3292

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, 1072
        • Hospital General de Agudos JM Ramos Mejia
      • Buenos Aires, Argentina, B7600
        • Instituto de Investigaciones Clinicas Mar del Plata
      • Buenos Aires, Argentina, 1202
        • Fundacion Huesped
      • Belo Horizonte - MG, Brasil, 30130-100
        • Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
      • Canela-Salvador, Brasil, 40110-060
        • Fundação Bahiana de Infectologia
      • Manauas, Brasil, 69040-000
        • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
      • Nova Iguaçu, Brasil, 26030-380
        • Hospital General de Nova Iguaçu - HGNI
      • Porto Alegre, Brasil, RS 91350 200
        • Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
      • Rio de Janeiro, Brasil, 21040-360
        • Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
      • São Paulo, Brasil, 01246-903
        • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
      • São Paulo, Brasil, 04121-000
        • Centro de Referência e Treinamento DST/AIDS
      • São Paulo, Brasil, 06519-332
        • Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • UAB Sexual Health Research Clinic
    • California
      • Loma Linda, California, Forente stater, 92354
        • Loma Linda University Clinical Trial Center Clinic
      • Los Angeles, California, Forente stater, 90069
        • Mills Clinical Research
      • Los Angeles, California, Forente stater, 90036
        • Ruane Clinical Research Group Inc.
      • Los Angeles, California, Forente stater, 90038
        • UCLA CBAM Vine Street Clinic
      • Los Angeles, California, Forente stater, 90059
        • Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
      • Los Angeles, California, Forente stater, 90502
        • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      • Palm Springs, California, Forente stater, 92262
        • BIOS Clinical Research
      • San Diego, California, Forente stater, 92103
        • UCSD Anti Viral Research Center
      • San Francisco, California, Forente stater, 94102
        • Optimus Medical Group
      • San Francisco, California, Forente stater, 94102
        • Bridge HIV at the San Francisco Department of Public Health
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • University of Colorado Clinical and Translational Research Centers (CTRC)
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Yale University, School of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20009
        • Whitman-Walker Institute Inc.
      • Washington D.C., District of Columbia, Forente stater, 20017
        • Washington Health Institute
    • Florida
      • Fort Lauderdale, Florida, Forente stater, 33308
        • Therafirst Medical Center
      • Fort Lauderdale, Florida, Forente stater, 33316
        • Gary Richmond, MD, PA
      • Ft. Pierce, Florida, Forente stater, 34982
        • Midway Immunology & Research Center, LLC
      • Jacksonville, Florida, Forente stater, 32207
        • CAN Community Health Clinic
      • Miami, Florida, Forente stater, 33136
        • University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
      • Miami Gardens, Florida, Forente stater, 33055
        • CAN Community Health
      • Orlando, Florida, Forente stater, 32803
        • Orlando Immunology Center
      • Sarasota, Florida, Forente stater, 34237
        • CAN Community Health
    • Georgia
      • Atlanta, Georgia, Forente stater, 30303
        • Emory University
      • Atlanta, Georgia, Forente stater, 30308
        • Emory University Hospital Midtown Infectious Disease Clinic
      • Atlanta, Georgia, Forente stater, 30030
        • The Hope Clinic at Emory University
    • Illinois
      • Chicago, Illinois, Forente stater, 60613
        • Howard Brown Health Center
      • Chicago, Illinois, Forente stater, 60612
        • RMR Core Center
      • Chicago, Illinois, Forente stater, 60612
        • University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University Infectious Diseases Research
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, Forente stater, 40241
        • Norton Infectious Disease Specialists
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70119
        • LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Johns Hopkins University School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • The Fenway Institute
    • Michigan
      • Berkley, Michigan, Forente stater, 48072
        • Be Well Medical Center
      • Detroit, Michigan, Forente stater, 48202
        • Henry Ford Hospital
    • Mississippi
      • Jackson, Mississippi, Forente stater, 39202
        • Open Arms Healthcare Center
    • Missouri
      • Kansas City, Missouri, Forente stater, 64111
        • KC CARE Health Center
    • New Jersey
      • Newark, New Jersey, Forente stater, 07102
        • St. Michael's Medical Center
      • Somers Point, New Jersey, Forente stater, 08244
        • South Jersey Infectious Disease
    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
      • Greensboro, North Carolina, Forente stater, 27401
        • Cone Health/Regional Center for Infectious Disease Research Center
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Wake Forest University Health Sciences
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267
        • University of Cincinnati
      • Columbus, Ohio, Forente stater, 43210
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Penn Prevention Unit
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Medical University of South Carolina, Infectious Disease Clinic
      • Columbia, South Carolina, Forente stater, 29203
        • Prisma Health-Midlands Clinical Research Unit
      • Greenville, South Carolina, Forente stater, 29605
        • Prisma Health Internal Medicine Clinic
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38105
        • St Jude Children's Research Hospital
      • Memphis, Tennessee, Forente stater, 38103
        • Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
      • Nashville, Tennessee, Forente stater, 37208
        • Meharry Medical College Clinical and Transitional Research Center
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Central Texas Clinical Research
      • El Paso, Texas, Forente stater, 79915
        • Centro San Vincente
      • Houston, Texas, Forente stater, 77098
        • The Crofoot Research Center, INC
      • Houston, Texas, Forente stater, 77009
        • UT Health Science Center at Houston
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Ofiice of Dr. Peter Shalit, MD
      • Guadalajara C.P., Mexico, 44160
        • Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
      • Barranco, Peru, 15063
        • Asociacion Civil Impacta Salud y Educacion - Sede Barranco
      • Callao, Peru, 7006
        • Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
      • Iquitos, Peru
        • Asociacion Civil Selva Amazonica
      • Lima, Peru, 15001
        • Via Libre
      • Lima, Peru, 15088
        • Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
    • PR
      • San Juan, PR, Puerto Rico, 00717
        • Ararat Research Center
      • San Juan, PR, Puerto Rico, 00909
        • Centro Ararat- San Juan
      • Cape Town, Sør-Afrika, 7925
        • Desmond Tutu Health Foundation
      • Johannesburg, Sør-Afrika, 2038
        • Wits Reproductive Health and HIV Institute (Wits RHI)
      • Pretoria, Sør-Afrika, 87
        • The Aurum Institute: Pretoria Clinical Research Centre
      • Soshanguvhe, Sør-Afrika, 0152
        • Setshaba Research Centre
      • Tembisa, Sør-Afrika, 1632
        • The Aurum Institute Tembisa CRC, Clinic 4
      • Vincent, Sør-Afrika, 5217
        • FPD-DTHF Ndevana Commuity Research Site
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial Hospital
      • Bangkok, Thailand, 10400
        • Ramathibodi Hospital, Mahidol University
      • Bangkok, Thailand, 10330
        • Institute of HIV Research and Innovation
      • Bangkok, Thailand, 10330
        • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
      • Chiang Mai, Thailand, 50200
        • Research Institute for Health Sciences, Chiang Mai University
      • Khon Kaen, Thailand, 40002
        • Srinagarind Hospital, Khon Kaen University
      • Nonthaburi, Thailand, 11000
        • Bamrasnaradura Infectious Disease Institute

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

16 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

Incidence Phase

  • CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.

  • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.

  • Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:

    • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
    • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
    • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

  • Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

Incidence Phase

  • Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
  • Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

  • Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks
  • Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily
  • Oral LEN 600 mg on Days 1 and 2

Participants will receive oral LEN if SC injections are not available.

Tablets administered orally without regard to food

Andre navn:
  • GS-6207

Administered via SC injections

Andre navn:
  • GS-6207; Yeztugo

Tablets administered orally

Eksperimentell: Randomized Blinded Phase: Placebo LEN + F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • SC LEN placebo every 26 weeks
  • Oral F/TDF 200/300 mg once daily
  • PTM Oral LEN on Days 1 and 2

Participants will receive oral LEN placebo if SC injections are not available.

Tablets administered orally

Andre navn:
  • Truvada®

Administered via SC injections

Tablets administered orally

Eksperimentell: LEN Open-Label Extension (OLE) Phase

Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase.

Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days).

Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2.

All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first.

After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit.

Tablets administered orally without regard to food

Andre navn:
  • GS-6207

Administered via SC injections

Andre navn:
  • GS-6207; Yeztugo
Eksperimentell: Pharmacokinetic (PK) Tail Phase

Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days).

Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit.

Tablets administered orally

Andre navn:
  • Truvada®

F/TAF tablets administered orally once daily

Andre navn:
  • Descovy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
Tidsramme: Incidence Phase Screening Visit (Day 1)

bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood.

HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:

  • Positive HIV-1/2 differentiation Ab, OR
  • Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR
  • HIV-1 RNA quantitative test ≥200 copies/mL.
Incidence Phase Screening Visit (Day 1)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
Tidsramme: Up to 149 weeks

HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

Up to 149 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
Tidsramme: Up to 149 weeks

HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

Up to 149 weeks
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
Tidsramme: Up to 149 weeks

A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

Up to 149 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: First dose date up to 184 weeks

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.

First dose date up to 184 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
Tidsramme: First dose date up to 184 weeks

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

First dose date up to 184 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Gilead Study Director, Gilead Sciences

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

28. juni 2021

Primær fullføring (Faktiske)

21. august 2024

Studiet fullført (Antatt)

1. august 2028

Datoer for studieregistrering

Først innsendt

28. mai 2021

Først innsendt som oppfylte QC-kriteriene

11. juni 2021

Først lagt ut (Faktiske)

14. juni 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • GS-US-528-9023
  • DOH-27-102021-6681 (Annen identifikator: South African National Clinical Trial Registry)
  • 2023 (U.S. NIH-stipend/kontrakt)
  • 2023-001025-23 (EudraCT-nummer)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .